Navigation Links
Trails to detect effective breast cancer drugs that reduces recurrences

A quest for new drug has started to determine and help patients to have a recurrence free survival after breast cancer surgery. The chemotherapy drugs docetaxel (Taxotere) and vinorelbine (Navelbine) are tested to analyze the outcomes.//

It was previously reported by the Finnish researchers that patients who received infusions of trastuzumab (Herceptin) were less likely to get recurrences in the New England Journal of Medicine.

Dr. Heikki Joensuu, corresponding author and a physician at Helsinki University Central Hospital said that the breast cancer recurrence reduced by 42% during the first 3 years of follow-up among women treated with docetaxel when compared to those who received vinorelbine.

But on the other hand it was found that docetaxel was associated with more adverse effects such as allergic reactions, swelling and fever.

Joensuu and his colleagues conducted a study in more than a thousand women with breast cancer.

They gave them three cycles of either docetaxel or vinorelbine, followed by three cycles of other cancer drugs.

Then, a subgroup of 232 women was identified whose tumors had an amplified HER2/neu gene. This gene is known to be associated with cancers that grow and spread aggressively.

They were also assigned either to receive nine weeks of infusions of Herceptin or a placebo. By doing this the researchers were able to identify the best regime for recurrence-free survival.

The result of the study was that patients who received Herceptin had 58 % fewer cancer recurrences during the three-year follow-up than those who didn't get the drug. Previous studies also show that adjuvant trastuzumab [Herceptin] if taken for a course of one year reduces the rate of breast cancer recurrence by 50 % in women having HER2-positive breast cancer.

But it is not clearly understood about the optimal duration of the drug usage. Dr. Mark Pegram, director of the women's cancer pr ogram at the Jonsson Cancer Center at the David Geffen School of Medicine at UCLA said that if it is the short nine week regime that turns out to be ideal then it is great news. But still this question remains to be confirmed.


'"/>




Related medicine news :

1. Clinical Renal Trails Do Not Have Sufficient Women Participants
2. Clinicians Participating In the Pharmaceutical-Sponsored Trails Tend To Prescribe Their Drugs
3. CDC To Conduct Pre-clinical Trails Of BioDiems Intranasal Bird Flu Vaccine
4. Vitamin B12 can help in detecting cancers
5. “Brain fingerprinting”- The new lie detectr
6. Ductal lavage may detect early breast cancer
7. Better prostate cancer detection
8. Early detection of prostate cancer
9. Early detection of heart attack
10. Cytobrush to detect oral cancer
11. New device for detecting artery blockages
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Miami Dental ... implants to their Miami dental office. Beginning in January, Miami Dental Specialists will ... Miami Dental Specialists are the first office to be chosen by the dental implant ...
(Date:2/12/2016)... ... February 12, 2016 , ... Atlantic Information Services, ... Plans and PBMs,” an upcoming Feb. 24 webinar that will discuss ways health ... therapeutic categories, such as the $1,000-per-pill hepatitis C treatment Sovaldi and high-cost PCSK9 ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... The Central Coast Autism Spectrum Center (CCASC) ... is to provide a night of fun for teens with and without special needs to ... welcomed and included at the event. The dance will take place on Saturday, Feb. 13 ...
(Date:2/12/2016)... CA (PRWEB) , ... February 12, 2016 , ... With the exception of restorative dentistry, ... of dental decay. With the recent approval by the FDA, there is a now ... similar to fluoride varnish, SDF is very simple and quick to apply. The application ...
(Date:2/11/2016)... ... February 11, 2016 , ... SPH Analytics ... action analytics leader’s population health solutions, MDinsight® and IndiGO®, for its primary care ... healthcare system. Details of the contract were not disclosed. , As the healthcare ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... , Feb. 12, 2016  SI-BONE, Inc., a medical device company ... ("iFuse"), a minimally invasive surgical (MIS) device indicated for fusion for ... Services, Inc. (NGS), the Medicare Administrative Contractor (MAC) covering the states ... Maine , Massachusetts , ... New York , Rhode Island , ...
(Date:2/12/2016)... and SEOUL, South Korea ... Menarini and Macrogen, Inc. today announced they will ... innovative procedures for precision medicine in cancer. The ... Biosystems, DEPArray™ digital-sorting technology with Macrogen,s high-throughput Next ... certified under the Clinical Laboratory Improvement Amendments (CLIA) ...
(Date:2/12/2016)... , Feb. 12, 2016  Apellis ... completed a $47.1 million Series D preferred ... Asset Management, Hillhouse Capital Group and venBio ... Venture Investments, AJU IB Investment, and Epidarex ... used to further advance clinical trials in ...
Breaking Medicine Technology: